Familial hyperaldosteronism

Journal of Steroid Biochemistry and Molecular Biology

Volumn 78, Issue 3, 2001, Pages 215-229

  Stowasser, Michael ^a   Gordon, Richard D ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Familial hyperaldosteronism type I; Familial hyperaldosteronism type II; Glucocorticoid remediable aldosteronism; Hypertension; Primary aldosteronism

Indexed keywords

ALDOSTERONE; AMILORIDE; CORTICOTROPIN; DEXAMETHASONE; GLUCOCORTICOID; HYDROCORTISONE; SPIRONOLACTONE; TISSUE KALLIKREIN;

CHROMOSOME 7; DISEASE SEVERITY; DOSE RESPONSE; ENZYME REPRESSION; FAMILIAL DISEASE; GENDER; GENE SEGREGATION; GENETIC REGULATION; HORMONE SYNTHESIS; HUMAN; HYBRID GENE; HYPERALDOSTERONISM; HYPERTENSION; MORPHOLOGY; MUTATION; PHENOTYPE; PREVALENCE; REVIEW;

EID: 0034786332     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(01)00097-8     Document Type: Short Survey

References (122)

1. Potassium-losing nephritis
2. Konstitution des aldosterons, des neuen mineralocorticoids
3. Primary aldosteronism, a new clinical entity
4. Aldosteronism and hypertension: Primary aldosteronism versus hypertensive disease with secondary aldosteronism
5. The evolution of primary aldosteronism: 1954-1967
6. Primary aldosteronism: Diagnosis and surgical treatment
7. Primary aldosteronism: Experience with current diagnostic criteria and surgical treatment in fourteen patients
8. The syndrome of primary aldosteronism
9. Primary aldosteronism: Diagnosis, localization and treatment
10. Primary aldosteronism due to adrenal hyperplasia: Occurrence in a boy aged 10 years
11. Clinical characteristics of primary aldosteronism from an analysis of 145 cases
12. Bilateral adrenal hyperplasia as a cause of primary aldosteronism with hypertension, hypokalemia and suppressed renin activity
13. Non-tumorous 'primary' aldosteronism: II. Type not relieved by glucocorticoid
14. Results of adrenal surgery in patients with hypertension, aldosterone excess, and low plasma renin concentration
15. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone
16. Evidence for an unidentified ACTH-induced steroid hormone causing hypertension
17. Familial, dexamethasone-suppressible, normokalemic hyperaldosteronism
18. Dexamethasone-suppressible hyperaldosteronism: Adrenal transitional cell hyperplasia?
19. Hypertension corrected and aldosterone responsiveness to renin-angiotensin restored by long-term dexamethasone in glucocorticoid-suppressible hyperaldosteronism
20. Clinical, biochemical and genetic approaches to the detection of Familial Hyperaldosteronism Type I
21. Evolution of primary aldosteronism as a highly specific clinical entity
22. Patterns of adrenal secretion and urinary excretion of aldosterone and plasma renin activity in normal and hypertensive subjects
23. Incidence of primary aldosteronism uncomplicated 'essential' hypertension
24. Prevalence of primary aldosteronism
25. Prevalence of primary and secondary hypertension: Studies in a random population
26. The incidence rate of phaeochromocytoma and Conns syndrome in Denmark, 1977-1981
27. The prevalence of hypertension in an unselected population, and the frequency of abnormalities of potassium, angiotensin II and aldosterone in hypertensive subjects
28. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity
29. Diagnosis under random conditions of all disorders of the renin-angiotensin-aldosterone axis, including primary aldosteronism
30. High incidence of primary aldosteronism in 199 patients referred with hypertension
31. Evidence that primary aldosteronism may not be uncommon-twelve percent incidence among antihypertensive drug trial volunteers
32. Primary aldosteronism and other forms of mineralocorticoid hypertension
33. Prevalence and diagnostic workup of primary aldosteronism
34. Primary aldosteronism: Update on diagnosis and treatment
35. Primary aldosteronism: A missed diagnosis in 'essential hypertensives'?
36. Potentially high prevalence of primary aldosteronism in a primary-care population
37. Screening for primary aldosteronism with a logistic multivariate discriminant analysis
38. The aldosterone/renin ratio as a screening test for primary aldosteronism
39. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore
40. Primary aldosteronism in essential hypertensives: Prevalence, biochemical profile and molecular biology
41. Familial forms broaden horizons in primary aldosteronism
42. Clinical and pathological diversity of primary aldosteronism including a new familial variety
43. Familial hyperaldosteronism type II-five families with a new variety of primary aldosteronism
44. A new form of congenital adrenal hyperplasia
45. A case of glucocorticoid-responsive hyperaldosteronism
46. A kindred with familial glucocorticoid-suppressible aldosteronism
47. A new family with dexamethasone-suppressible hyperaldosteronism: Aldosterone unresponsiveness to angiotensin II
48. Dexamethasone-suppressible hyperaldosteronism: Studies on overproduction of 18-hydroxycortisol in three affected family members
49. A chimaeric 11β-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension
50. Overproduction of sodium-retaining steroids by the zona glomerulosa is adrenocorticotropin-dependent and mediates hypertension in dexamethasone-suppressible aldosteronism
51. Anomalous postural aldosterone response in glucocorticoid-suppressible hyperaldosteronism
52. Renin-aldosterone response to dexamethasone in glucocorticoid-suppressible hyperaldosteronism is altered by coexistent renal artery stenosis
53. Control of plasma aldosterone in primary aldosteronism: Distinction between adenoma and hyperplasia
54. The plasma aldosterone response to angiotensin II infusion in aldosterone-producing adenoma and idiopathic hyperaldosteronism
55. Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: Adrenal hyperplasia) or low-renin essential hypertension
56. Effects of glucocorticoid administration on aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism
57. ACTH-dependent aldosterone excess due to adrenocortical adenoma: A variant of primary aldosteronism
58. Transient fall and subsequent return of high aldosterone secretion by adrenal adenoma during continued dexamethasone administration
59. Effects of corticotropin on aldosterone excretion and plasma renin in normal subjects, in essential hypertension and in primary aldosteronism
60. Adrenocorticotrophin and steroid-induced hypertension in humans
61. In familial hyperaldosteronism type I, hybrid gene-induced aldosterone production dominates that induced by wild type genes
62. Impaired potassium-stimulated aldosterone production: A possible explanation for normokalemic glucocorticoid-remediable aldosteronism
63. Hypersecretion of a new corticosteroid, 18-hydroxycortisol in two types of adrenocortical hypertension
64. Biosynthesis of 18-oxocortisol by aldosterone-producing adrenal tissue
65. Elevated urinary excretion of 18-oxocortisol in glucocorticoid-suppressible aldosteronism
66. Distinguishing aldosterone-producing adenoma from other forms of hyperaldosteronism and lateralizing the tumour pre-operatively
67. Adrenal corticosteroid synthesis and hypertension
68. Defective fasciculata zone function as the mechanism of glucocorticoid-remediable aldosteronism
69. Glucocorticoid-suppressible hyperaldosteronism and adrenal tumours occurring in a single French pedigree
70. Aldosterone-producing adenomas responsive to angiotensin pose problems in diagnosis
71. Production of 18-oxo-cortisol in subtypes of primary aldosteronism
72. Histological and biochemical distinctiveness of atypical aldosterone-producing adenomas responsive to upright posture and angiotensin
73. Characterization of two genes encoding human steroid 11β-hydroxylase (P-45011β)
74. aldo as related to primary aldosteronism
75. Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase
76. Glucocorticoid-suppressible hyperaldosteronism: Ultrastructural observation of a case
77. Primary aldosteronism: Learning from the study of familial varieties
78. Non-tumorous 'primary' aldosteronism: I, Type relieved by glucocorticoid (glucocorticoid-remediable aldosteronism)
79. Evaluation of the dexamethasone suppression test for the diagnosis of glucocorticoid-remediable aldosteronism
80. Diagnosis of glucocorticoid-remediable aldosteronism in primary aldosteronism: Aldosterone response to dexamethasone and long polymerase chain reaction for chimeric gene
81. A PCR-based method of screening individuals of all ages, from neonates to the elderly, for Familial Hyperaldosteronism Type I
82. Rapid diagnosis of glucocorticoid suppressible hyperaldosteronism in infants and adolescents
83. A new genetic test for Familial Hyperaldosteronism Type I aids in the detection of curable hypertension
84. Rapid diagnosis and identification of cross-over sites in patients with glucocorticoid-remediable aldosteronism
85. Biochemical evidence of aldosterone overproduction and abnormal regulation in normotensive individuals with familial hyperaldosteronism type I
86. Severity of hypertension in familial hyperaldosteronism type I: Relationship to gender and to degree of biochemical disturbance
87. Glucocorticoid-remediable aldosteronism (GRA): Diagnosis, variability of phenotype and regulation of potassium homeostasis
88. Glucocorticoid-suppressible hyperaldosteronism: Effects of crossover site and parental origin of chimaeric gene on phenotypic expression
89. Glucocorticoid-remediable aldosteronism in a large kindred: Clinical spectrum and diagnosis using a characteristic biochemical phenotype
90. Glucocorticoid-suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2
91. Evidence for persistent wild type aldosterone synthase gene dysfunction in glucocorticoid-treated familial hyperaldosteronism type I
92. Treatment of familial hyperaldosteronism type I: Only partial suppression of hybrid gene required to correct hypertension
93. Abnormality of aldosterone and cortisol late pathways in glucocorticoid-remediable aldosteronism
94. Altered 11β-hydroxylase activity in glucocorticoid-suppressible hyperaldosteronism
95. Primary aldosteronism
96. Dexamethasone-suppressible hypertension
97. Inherited forms of mineralocorticoid hypertension
98. Pathological hypertrophy and cardiac interstitium: Fibrosis and renin-angiotensin-aldosterone system
99. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism
100. Familial hyperaldosteronism, not suppressed by dexamethasone
101. Familial Conn's syndrome
102. Lineage of familial aldosterone-producing adenoma
103. Genetic studies in familial aldosteronism not suppressible by dexamethasone
104. Primary aldosteronism
105. Diagnostic investigations in primary aldosteronism
106. Genetic analysis of aldosterone synthase in patients with idiopathic hyperaldosteronism
107. Aldosterone synthase gene in patients suffering from hyperaldosteronism
108. 320Ala convert the cortisol producing enzyme, CYP11B1, into an aldosterone producing enzyme
109. Mutations in CYP11B1 gene converting 11β-hydroxylase into an aldosterone-producing enzyme are not present in aldosterone-producing adenomas
110. Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2
111. Variation at the aldosterone synthae gene locus (CYP11B2) in hypertension
112. PCR-SSCP analysis of the angiotensin II type 1 receptor gene in patients with aldosterone-producing adenomas
113. Somatic mutations of the angiotensin II (AT1) receptor gene are not present in aldosterone-producing adenoma
114. Allelic losses on chromosome 11q13 in aldosterone-producing adrenal tumors
115. Different allelic patterns at chromosome 11q13 in paired aldosterone-producing tumours and blood DNA
116. PCR-SSCP analysis of the p53 gene in tumours of the adrenal gland
117. Linkage analysis of familial hyperaldosteronism type II-absence of linkage of the gene encoding the angiotensin II receptor type 1
118. Familial hyperaldosteronism type-II: Description of a large kindred and exclusion of the aldosterone synthase (CYP11B2) gene
119. A novel genetic locus for low-renin hypertension: Familial hyperaldosteronism type-II maps to chromosome 7 (7p22)
120. Analysis of the cAMP-dependent protein kinase system using molecular genetic approaches
121. Mutations of the gene encoding the protein kinase A type 1-α regulatory subunit in patients with the Carney complex